Physician
Oncology
Dr. Joanne Zujewski, MD
|
|
Give Review
Joanne Zujewski practices Oncology. She graduated from University of Minnesota Medical School. University of Minnesota Medical School has a rank of 40 in research and a 10 in primary care Joanne Zujewski is a published doctor. She has 43 publications published. The most current publication "Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 ..."
Publications
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 ...
- Inflammatory breast cancer: yet another risk of the obesity epidemic?
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group.
- Triple Negative Breast Cancer: Breast Cancer Research in Evolution 4/26/2011.
- Breast cancer in men in the United States: a population-based study of diagnosis, treatment, and survival.
- Multidisciplinary meeting on male breast cancer: summary and research recommendations.
- Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer.
- Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions.
- Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.
- Current NCI-sponsored Cooperative Group trials of endocrine therapies in breast cancer.
- The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology.
- Proposal for the use of progression-free survival in unblinded randomized trials.
- Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
- What breast-cancer survivors can expect.
- CNS metastasis: an old problem in a new guise.
- Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer.
- Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breas...
- Docetaxel-related skin, nail, and vascular toxicity.
- "Build quality in"--HER2 testing in the real world.
- Hormonal therapy of breast cancer.
- Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention.
- Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.
- Clinical trials referral resource. Current phase III breast cancer clinical trials.
- Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types.
- Effect of raloxifene on salivary sex steroid concentrations in premenopausal women.
- Sentinel lymph node biopsy in the management of ductal carcinoma in situ.
- Assessing breast cancer risk: genetic factors are not the whole story.
- Preoperative FLAC/granulocyte-colony-stimulating factor chemotherapy for stage II breast cancer: a prospective randomized trial.
- Research issues affecting preoperative systemic therapy for operable breast cancer.
- Gynecologic and hormonal effects of raloxifene in premenopausal women.
- Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer.
- A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
- The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer.
- A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.
- Raloxifene and its role in breast cancer prevention.
- A pilot study of dose intense doxorubicin and cyclophosphamide followed by infusional paclitaxel in high-risk primary breast cancer.
- Workshop on imaging science development for cancer prevention and preemption.
- Recommendations for collection and handling of specimens from group breast cancer clinical trials.
- Trial assessing individualized options for treatment for breast cancer: the TAILORx trial.
- Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer.
- Recruitment to a physical activity intervention study in women at increased risk of breast cancer.
- Ductal carcinoma in situ: trends in treatment over time in the US.
Schools
University of Mn Med Sch
University Wash
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Washington -
University of Minnesota Medical School
Helpful Reviews
Similar Doctors
|
|
Anne M. Noonan, MB BCH
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stanley Lipkowitz, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Howard L. Parnes, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Christian S. Hinrichs, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James H. Doroshow, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. C N. Coleman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard A. Binder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carolyn B. Hendricks, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard J. Hodes, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|